Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Migraine, With or Without Aura Clinical Trial

Official title:
A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention

Status Completed

Clinical Trial Summary

This study will evaluate the safety and tolerability of the following doses of atogepant (AGN-241689): 10 mg once daily (QD), 30 mg QD, 30 mg twice daily (BID), 60 mg QD, and 60 mg BID for the prevention of episodic migraine and will characterize the dose/response relationship.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02848326
Study type	Interventional
Source	Allergan
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	September 6, 2016
Completion date	April 23, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02873221` - An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine	Phase 3
Completed	`NCT03237845` - Safety and Efficacy in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT02828020` - Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3
Completed	`NCT03235479` - Safety and Efficacy Study in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03461757` - Trial in Adult Subjects With Acute Migraines	Phase 3
Completed	`NCT03266588` - Open Label Safety Study in Acute Treatment of Migraine	Phase 2/Phase 3
Completed	`NCT02867709` - Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine	Phase 3